Skip to main content

Table 1 Characteristics of included clinical trials in meta-analysis

From: Long-Term Nucleos(t)ide Analogues Therapy for Adults With Chronic Hepatitis B reduces the Risk of Long-Term Complications: a meta-analysis

Study Region Study type NA regimens (/day) Sample size (n) (treatment vs. placebo) Mean age (ys) (treatment vs. placebo) Male(%) (treatment vs. placebo) Mean ALT(U/L) (treatment vs. placebo) Pre-existing cirrhosis(%) (treatment vs. placebo) HBeAg (+) (%) (treatment vs. placebo) Mean treatment duration (mon) Follow up period (ys)
Papatheodoridis et al.[24] Greece Cohort LAM 100 or 150 mg then add or switch to ADV 396 (201 vs. 195) 55.9 (52 ± 11) vs. (49 ± 14) 82.6 (83.1 vs. 82.1) 83.2 (98 vs. 68) 33.3 (31.8 vs. 34.9) 0 48 3.8
Matsumoto et al.[25] Japan Case-control LAM 100 mg 754 (377 vs. 377) 41.5 (41.5 ± 12.0) vs. (41.4 ± 12.2) 72.8 (73.2 vs. 72.4) 171.6 (191.7 ± 234.8) vs. (151.5 ± 180.5) 17.5 (17.2 vs. 17.8) 54.8 (51.2 vs. 58.4) 18.9 2.7
Yuen et al.[26] Hong Kong Cohort LAM 100 mg 266 (142 vs. 124) 33.7 (33.9 vs. 33.4) 73.7 (74.7 vs. 72.6) 61 (65 vs. 56.5) 0 100 (100 vs. 100) 89.9 8.2
Liaw et al.[23] Taiwan RCT LAM 100 mg 651 (436 vs. 215) 43.3 (43 vs. 44) 85 (85 vs. 85) 69.3 (70 vs. 68) 61.3 (60 vs. 65) 58 (58 vs. 58) 32.4 2.7
Eun et al.[27] Korea RCT LAM 100 mg then add or switch to ADV 222 (111 vs. 111) M M M 100 M M 4.4
Jong Ryul Eun et al.[28] Korea Cohort LAM 1355 (768 vs. 587) 36.8 (39.2 vs. 33.6) M 152.7 (161.3 vs. 141.4) 50.9 (67.3 vs. 25.2) 85.2 (80.1 vs. 91.8) More than 48 4.4
  1. M: Data missing in the studies; LAM: Lamivudine; ADV: Adefovir dipivoxil